Maria Kolnes Lie is doing research on how the tumor microenvironment regulates the epithelial-mesenchymal transition (EMT) by focusing on the Axl tyrosine kinase receptor, and how this relates to cancer therapy responses.
- (2021). Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with EGFR TKI and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells. Cancers. 24 pages.
- (2020). AXL is a driver of stemness in normal mammary gland and breast cancer. iScience. 1-40.
- (2020). AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology. 973-999.
- (2019). Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
- (2021). Development and Characterization of an ex vivo Organotypic Non-Small Cell Lung Cancer Model to Study the Effect of Elevated Oxygen Treatment.
- (2019). The role of AXL and the microenvironment in cancer cell plasticity and therapy responses. A study in non-small cell lung cancer models.
- (2020). Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. 22 pages.
- (2017). The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. 28 pages.
- (2020). Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. Cancer Drug Resistance. 22 pages.
- (2017). Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm. 53-66.
Born in 1989.
2013: M.S. in Nanoscience, University of Bergen. Thesis title: “In vitro phenotypic patterning of vascular cells by nano- and micro-design of the matrix substratum”
Since January 2015: PhD student, Cellular Networks Group